# Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

> **NCT01214174** · PHASE2 · TERMINATED · sponsor: **ICON Bioscience Inc** · enrollment: 42 (actual)

## Conditions studied

- Ocular Inflammation

## Interventions

- **DRUG:** IBI-10090

## Key facts

- **NCT ID:** NCT01214174
- **Lead sponsor:** ICON Bioscience Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Study C11-01 started
- **Last updated:** 2013-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214174, "Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01214174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*